Haima Therapeutics

Biotechnology ResearchOhio, United States11-50 Employees

Haima Therapeutics is a Cleveland-based biotechnology company operating at a pre-clinical stage, pursuing bio-inspired approaches to bleeding and other blood-related conditions. The firm has developed SynthoPlate, a nanoparticle-based hemostatic technology designed to localize at sites of injury and boost the body's natural clotting response to stop hemorrhage. It operates from the BioEnterprise incubator in the University Circle area, near Case Western Reserve University, University Hospitals, and the Cleveland Clinic, with collaboration with CWRU a longstanding element of its development. The company sits within the biotechnology research landscape, focusing on therapies that imitate platelet function to mitigate bleeding dysfunctions.

Haima's technology targets bleeding management in clinical settings, with potential applications in trauma care, surgery, and conditions involving low platelet counts. In 2020, Haima entered into an exclusive license agreement with Case Western Reserve University to research, develop, and market artificial platelet technologies, reflecting a formal collaboration to advance its platform. The organization is described as a small to mid-sized enterprise within the life sciences sector that relies on academic partnerships to pursue its pre-clinical programs.

Sign up for free to view info

Email Format Employee directory